Thyroid Nodule Size Irrelevant When It Comes to Malignancy

Nancy A. Melville

January 02, 2019

Large thyroid nodules in asymptomatic patients show malignancy and false-negative rates on fine needle aspiration (FNA) that are similar to those of small nodules, suggesting that nodule size alone should not be a reason for surgical resection, according to findings from a new meta-analysis.

"Based on these data, surgical resection of large cytologically benign nodules is not recommended in the absence of other clinical indications," for thyroidectomy, say Nicole A. Cipriani, MD, assistant professor of pathology, University of Chicago, Illinois, and coauthors of the study, recently published in Thyroid.

With conflicting data on whether larger nodule size is associated with a greater risk of malignancy and false-negative FNA rates, some surgeons choose to err on the side of caution and resect larger thyroid nodules, regardless of FNA results.

But the issue is controversial. Surgery itself is associated with potential risks, including increased physical and psychological morbidity, as well as a heavier financial burden, compared with the alternative approach of close clinical follow-up of cytologically benign nodules.

To assess the existing evidence, Cipriani and a team of multiple reviewers analyzed findings from 35 studies that stratified thyroid nodules by size and included data on benign and other cytology.

The analysis included more than 20,000 nodules, of which more than 7000 had benign cytology.

Of 21 datasets that allowed for comparison of malignancy rates by thyroid nodule size, 81% showed malignancy rates of larger nodules to be similar to or lower than rates of smaller nodules. The overall malignancy rate of large nodules (3 cm or greater) was 13.1% compared with 19.6% among nodules 3 cm or smaller (odds ratio [OR], 0.72).

And in studies stratifying nodules as 4 cm or greater, the malignancy rate was similar, at 20.9%, to that of nodules 4 cm or smaller, at 19.9% (OR, 0.85).

False-negative FNA rates according to nodule size were available in 17 datasets, with only one study linking higher false-negative rates with larger nodules.

In those studies, the overall false-negative rate of nodules 3 cm or greater was 7.2% compared with 5.7% of those smaller than 3 cm (OR, 1.47; CI, 0.80 - 2.69). And the overall false-negative rate of nodules 4 cm or greater was only slightly higher than that of nodules smaller than 4 cm, at 6.7% vs 4.5% (OR, 1.38; CI, 1.06 - 1.80), which was again not statistically significant.

Of note, papillary thyroid carcinoma and non-invasive encapsulated follicular variant of papillary thyroid carcinoma were the most commonly reported false-negative diagnoses (39.4% and 23.7%, respectively).

Guidelines Reflect Unclear Evidence

Although some studies have attempted to correlate larger thyroid nodule size with the risk of malignancy or false-negative FNA, the overall inconsistency of evidence is reflected in the American Thyroid Association (ATA) guidelines, which state that "based on the evidence, it is still unclear if patients with thyroid nodules 4 cm or larger and benign cytology carry a higher risk of malignancy and should be managed differently than those with smaller nodules."

"In light of these findings, it is surprising that multiple authors recommend surgical resection of large cytologically benign nodules due to perceived (but not actual) high false-negative rates," say Cipriani and colleagues.

They note that based on these findings they have collectively "stopped recommending thyroidectomy for large cytologically being nodules based on size alone."

As reported by Medscape Medical News in July, authors of a prior study of 652 indeterminate thyroid nodules from 589 patients came to a similar conclusion.

The study showed no significant differences in the rate of malignancies between nodules smaller than 4 cm (140 of 546; 26.5%) compared with those 4 cm or larger (33 of 106; 31.1%).

It also indicated that most malignancies among indeterminate thyroid nodules were low-risk regardless of tumor size, with the researchers concluding size should not be driving more aggressive diagnostic surgeries for cytologically indeterminate thyroid nodules.

Some Benign Nodules Are Exceptions for Resections

ATA guidelines recommend resection primarily for nodules assessed on FNA to be malignant, Cipriani and coauthors state.

But there are some exceptions for cytologically benign nodules, including those that are symptomatic, growing in size, of cosmetic concern, or substernal, with symptoms of concern including difficulty swallowing or breathing, or tracheal deviation, they stress.

"Close follow-up (including repeat ultrasound and/or FNA) can identify patients who ultimately require resection, and those with indolent disease may avoid surgery for cytologically benign but large thyroid nodules," they conclude.

The authors have reported no relevant financial relationships.

Thyroid. Published online December 14, 2018. Abstract

For more diabetes and endocrinology news, follow us on Twitter and on Facebook.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.